Niche Oncology Supportive-care FocusOncoZenge's clear strategic focus on oncology supportive care and a lead candidate targeting oral mucositis addresses a predictable, recurring complication of cancer therapy. That structural clinical need supports durable demand if regulatory and reimbursement milestones are reached.

Initial Revenue Generation In 2025Recording SEK 2.7m of revenue in 2025 versus prior near-zero levels suggests early commercial activity or milestone receipts. This demonstrates some capacity to monetize assets beyond R&D, which durably de-risks an otherwise pre-revenue profile if clinical progress continues.

Signs Of Reduced Losses Versus Peak LevelsSmaller losses in 2025 compared with 2022 indicate improving operating performance or tighter cost management. If sustained, this structural improvement can lengthen runway, reduce funding frequency, and create a clearer path toward margin recovery as commercialization or scale-up occurs.

Bears Say

Weakened Balance Sheet, Negative EquityNegative shareholders' equity and new debt materially increase solvency and refinancing risk. This structural deterioration reduces financial flexibility, raises cost of capital, and heightens the likelihood of dilutive or onerous financing decisions, impairing long-term funding of trials and commercialization.

Persistent Operating Cash BurnConsistent negative operating cash flow (≈ -SEK 13.1m in 2025) and weak free cash flow signal continued reliance on external financing. This is a durable constraint on execution, increasing dilution risk and limiting the company's ability to invest in manufacturing, trials, or commercial scale without new capital.

Small, Volatile Revenue And Deep LossesLow, inconsistent revenue combined with deeply negative EBIT underscores a long path to breakeven and heavy dependence on successful product approval and market uptake. The single-product focus and margin deficits create a structural sustainability risk absent clear commercialization progress.

8LY FAQ

What was OncoZenge AB’s price range in the past 12 months?

OncoZenge AB lowest stock price was €0.34 and its highest was €0.67 in the past 12 months.

What is OncoZenge AB’s market cap?

OncoZenge AB’s market cap is €7.24M.

When is OncoZenge AB’s upcoming earnings report date?

OncoZenge AB’s upcoming earnings report date is May 19, 2026 which is in 73 days.

How were OncoZenge AB’s earnings last quarter?

OncoZenge AB released its earnings results on Feb 26, 2026. The company reported -€0.073 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.073.

Is OncoZenge AB overvalued?

According to Wall Street analysts OncoZenge AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does OncoZenge AB pay dividends?

OncoZenge AB does not currently pay dividends.

What is OncoZenge AB’s EPS estimate?

OncoZenge AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does OncoZenge AB have?

OncoZenge AB has 12,647,174 shares outstanding.

What happened to OncoZenge AB’s price movement after its last earnings report?

OncoZenge AB reported an EPS of -€0.073 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.344%.

Which hedge fund is a major shareholder of OncoZenge AB?

Currently, no hedge funds are holding shares in DE:8LY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

OncoZenge AB

OncoZenge AB (publ), a pharmaceutical company, develops healthcare products for cancer supportive care. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of oral mucositis. The company was founded in 2020 and is headquartered in Bromma, Sweden. OncoZenge AB (publ) is a subsidiary of Moberg Pharma AB (publ).